Charles River Laboratories launched its lentiviral vector (LVV) manufacturing platform, Lentivation. The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows. Lentivation leverages Charles River’s screening toolbox for tackling challenging gene-of-interest plasmids, off-the-shelf (OTS) LVV packaging plasmids, phase-appropriate produ...